# Magnitude Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/magnitude-biosciences

- Industry: Biotechnology
- Headquarters: UK
- Website: www.magnitudebiosciences.com
- Total disclosed funding: $2.3M
- Investors on record: 6

## About

Based in Sedgefield, UK and Founded in 2018, and co-founded by David Weinkove, Chris Saunter. and Fozia Saleem serves as the CEO of the company. Magnitude Biosciences Ltd. specializes in drug development and research processes, leveraging C. elegans-based assays. In September 2026, Magnitude Biosciences Limited raised GBP 1.3 million in venture funding led by Northstar Ventures, with participation from Maven Capital Partners. Magnitude Biosciences specializes in advanced C. elegans-based assays designed to enhance drug development and research across various sectors, including biotechnology, pharmaceuticals, and academia. Their core offerings include high-throughput screening for age-related compounds, toxicity assessments, and microbiome studies, all conducted using their proprietary WormGazer™ technology. The assays provide valuable insights into the effects of compounds on neurodegeneration, chronic toxicity, and ageing, enabling clients to obtain reproducible data crucial for decision-making. The company's services are tailored to meet the needs of diverse clients, including health and nutrition firms, biotech companies, and academic institutions, focusing on delivering results efficiently within three weeks. Magnitude Biosciences operates in key markets including North America, Europe, and parts of Asia, providing tailored support to clients seeking innovative solutions in their research and development efforts. Magnitude Biosciences generates revenue through contract lab services structured primarily as B2B transactions with clients in the biotechnology, pharmaceutical, and academic sectors. Clients engage the company to conduct customized C. elegans studies, leveraging its expertise to gather high-quality, reproducible data on various research questions. The revenue model is based on project-based fees associated with specific assays, including flagship offerings related to microbiome research and neurodegenerative disease studies. Transaction structures may include upfront payments for specific projects or milestone-based payments as data is generated and delivered. By leveraging their unique technology and specialized expertise, Magnitude Biosciences fosters long-term partnerships with clients, ensuring a steady revenue stream through ongoing research projects. The company is planning to use the September 2026 funding to expand VivoScan operations, strengthen engagement with global pharmaceutical companies, invest in equipment and automation, and grow its workforce.

## Funding rounds

- Round, Sep 15, 2026, $1.8M — Northstar Ventures, angel investors, Finance Durham Fund, NPIF II – Maven Equity Finance
- Series A, Sep 27, 2019, $0.3M — Northstar Ventures, Saker Capital Ltd.
- Seed, Nov 30, 2018, $0.2M — Northstar Ventures, European Regional Development Fund, Saker Capital Ltd.

## Investors

- Northstar Ventures (https://capitalatlas.ai/funds/northstar-ventures) — Seed, Series A
- European Regional Development Fund — Seed
- Saker Capital Ltd. — Seed, Series A
- angel investors (https://capitalatlas.ai/funds/angel-investors)
- Finance Durham Fund
- NPIF II – Maven Equity Finance